RICTOR and neoplasm: In the patient with DSRCT the PI3K/Akt/mTOR pathway is constitutively activated by virtue of the expression of p-Akt (Ser 473) in the nuclear compartment of the tumor cells, and p-mTOR phosphorylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as the dominant form.